# DCE-MRI PET Bevacizumab Study in Rectal Cancer

> **NCT01426074** · PHASE2 · WITHDRAWN · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **DRUG:** Bevacizumab 5 mg/kg

## Key facts

- **NCT ID:** NCT01426074
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08
- **Primary completion:** 2014-06-11
- **Final completion:** 2014-06-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01426074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01426074, "DCE-MRI PET Bevacizumab Study in Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01426074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*